✦ LIBER ✦

the role of autologous tumor cells in preventing lymphokine-activated killer cell induction in vitro

✍ Scribed by Susan F. Slovin; Henry C. Maguire Jr.; Michael J. Mastrangelo

Publisher: John Wiley and Sons
Year: 1990
Tongue: English
Weight: 590 KB
Volume: 66
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19901215)66:12<2541::aid-cncr2820661216>3.0.co;2-r

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lymphokine-activated killer cell inducti

Lymphokine-activated killer cell induction in tumor-infiltrating leukocytes from colon cancer patients

✍ Edgar D. Staren; Steven G. Economou; Jules E. Harris; Donald P. Braun 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 541 KB

The role of pentoxifylline in the preven

The role of pentoxifylline in the prevention of tumor cell implantation

✍ M. C. Ikossi-O'Connor; J. L. Ambrus 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB

Effects of surgery on the generation of

Effects of surgery on the generation of lymphokine-activated killer cells in patients with breast cancer

✍ Mr P. G. McCulloch; A. Macintyre 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 379 KB 👁 2 views

Inducible lymphokine-activated killer (L

Inducible lymphokine-activated killer (LAK) cell activity in the peripheral blood of patients with relapsed/refractory non-Hodgkin's lymphoma (NHL)

✍ Kenneth W. Zamkoff; Nora P. Watman; David B. Duggan; Bernard J. Poiesz; Arlan J. 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 453 KB

Therapy with recombinant interleukin-2 (rIL-2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non-Hodgkin's lymphoma (NHL) have been treated with rIL-2. The present study sought to determine if peripheral blood mononuclear cell

Phase iii randomized trial of interleuki

Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma

✍ Teresa Murray Law; Robert J. Motzer; Madhu Mazumdar; Kenneth W. Sell; Philip Wal 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 723 KB

Background. Treatment with interleukin-2 (IL-2) and lymphokine-activated killer cells (LAK) resulted in responses in some patients with advanced renal cell carcinoma (RCC). However, the relative therapeutic benefit of the addition of LAK to IL-2 was unknown. Methods. A randomized Phase I11 trial wa

Autologous tumor killing activity as a p

Autologous tumor killing activity as a prognostic factor in primary resected nonsmall cell carcinoma of the lung

✍ Takehiko Fujisawa; Yutaka Yamaguchi 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 2 views

## Background: Cytotoxic activity of peripheral blood lymphocytes obtained during surgery against autologous fresh tumor cells has been reported. however, the role of lymphocyte autologous tumor killing or natural killer activity during the postoperative period remains obscure. in this article, the